The Texas Medical Center Library

DigitalCommons@TMC
The University of Texas MD Anderson Cancer
Center UTHealth Graduate School of
Biomedical Sciences Dissertations and Theses
(Open Access)

The University of Texas MD Anderson Cancer
Center UTHealth Graduate School of
Biomedical Sciences

5-2016

No Difference in Health Related Quality of Life Between
Therapeutic Options for Type 1 Gaucher Disease
Victoria Wagner

Follow this and additional works at: https://digitalcommons.library.tmc.edu/utgsbs_dissertations
Part of the Medical Genetics Commons

Recommended Citation
Wagner, Victoria, "No Difference in Health Related Quality of Life Between Therapeutic Options for Type 1
Gaucher Disease" (2016). The University of Texas MD Anderson Cancer Center UTHealth Graduate School
of Biomedical Sciences Dissertations and Theses (Open Access). 654.
https://digitalcommons.library.tmc.edu/utgsbs_dissertations/654

This Thesis (MS) is brought to you for free and open
access by the The University of Texas MD Anderson
Cancer Center UTHealth Graduate School of Biomedical
Sciences at DigitalCommons@TMC. It has been
accepted for inclusion in The University of Texas MD
Anderson Cancer Center UTHealth Graduate School of
Biomedical Sciences Dissertations and Theses (Open
Access) by an authorized administrator of
DigitalCommons@TMC. For more information, please
contact digitalcommons@library.tmc.edu.

NO DIFFERENCE IN HEALTH RELATED QUALITY OF LIFE BETWEEN THERAPEUTIC
OPTIONS FOR TYPE 1 GAUCHER DISEASE
by
Victoria Frances Wagner, BA
APPROVED:

______________________________
Hope Northrup, MD
Advisory Professor

______________________________
Jessica Davis, MS, CGC

______________________________
Syed Hashmi, MD, PhD

______________________________
Mary Kay Koenig, MD

______________________________
Joanne Nguyen, MD

APPROVED:

____________________________
Dean, The University of Texas
Graduate School of Biomedical Sciences at Houston

NO DIFFERENCE IN HEALTH RELATED QUALITY OF LIFE BETWEEN THERAPEUTIC
OPTIONS FOR TYPE 1 GAUCHER DISEASE
A
THESIS
Presented to the Faculty of
The University of Texas
Health Science Center at Houston
and
The University of Texas
MD Anderson Cancer Center
Graduate School of Biomedical Sciences
in Partial Fulfillment
of the Requirements
for the Degree of
MASTER OF SCIENCE
by
Victoria Frances Wagner, BA
Houston, Texas
May 2016

ACKNOWLEDGEMENTS
This study was supported in part by a grant from Genzyme Corporation of Cambridge, MA. No
members or representatives of the Genzyme Corporation were involved with the design,
execution, analysis, or interpretation of this research. This work was completed in partial
fulfillment of the requirements for the author’s Master of Science degree from the University of
Texas Graduate School of Biomedical Sciences. This study would not have been possible
without participation from subjects from the type 1 Gaucher disease community.


iii

NO DIFFERENCE IN HEALTH RELATED QUALITY OF LIFE BETWEEN THERAPEUTIC
OPTIONS FOR TYPE 1 GAUCHER DISEASE
Victoria Frances Wagner, BA
Advisory Professor: Hope Northrup, MD

Type 1 Gaucher disease (GD) is the most common lysosomal storage disorder.
Previously, treatment for GD was limited to intravenous enzyme replacement therapy (ERT).
ERT reduces symptoms and increases healthrelated quality of life (HRQoL) in people with this
condition. In 2014, oral substrate reduction therapy (SRT) was approved for type 1 GD
treatment. Although both therapies alleviate disease symptoms, effects of SRT on HRQoL and
preferences for therapy are not well established. Electronic surveys were administered to adults
®
with type 1 GD. HRQoL was scored with the Short Form36 Version 2
Health Survey and

descriptive statistics were used to evaluate additional survey items. No differences in physical
HRQoL (
p
= 0.756) or mental HRQoL (
p
= 0.650) were observed between SRT and ERT users.
SRT users most often perceived their health to be similar to when they used ERT. Additionally,
SRT users expressed convenience and noninvasiveness as reasons for choosing SRT, while
many ERT users cited potential side effects and satisfaction with ERT as reasons for declining
SRT. There appears to be no difference in HRQoL between ERT and SRT users and no
perceived change in HRQoL for SRT users that previously used ERT. Participant responses
illustrate that one particular treatment may not be ideal for all patients with type 1 GD depending
on perceived convenience, invasiveness, or side effects. This evidence suggests that individuals
with type 1 GD be adequately counseled about the risks and benefits of both therapy options now
that SRT is clinically available.
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INTRODUCTION
Lysosomal storage diseases (LSDs) are a group of genetic disorders that affect the ability
of lysosomes to break down waste inside of various cells of the body. There are approximately
50 different types of LSDs that are clinically recognized and the most common of these is
Gaucher Disease (GD) [Grabowski, 1993]. GD involves a deficiency of the enzyme
glucocerebrosidase and, as a result, impedes the ability of lysosomes to break down a
glycosphingolipid called glucosylceramide that can accumulate within the cells of organs such as
the spleen, liver, kidneys, brain, lungs, and bone marrow [Beutler, 1991].
GD is most common in Ashkenazi Jewish populations and, depending on the mutation
and phenotypic classification, individuals with GD can be broken down into three different types
[Azuri et al, 1998; Koprivica et al, 2000]. Type 1 GD is the most common form of the disease
and is often referred to as non-neuropathic due to the fact that there are no neurological
symptoms of the disease in these patients. Types 2 and 3 are considered acute and chronic
neuropathic forms of the disease, respectively, and can result in neurologic symptoms such as
seizures or movement disorders [Beutler, 1991; Grabowski, 1993]. Symptoms that can be present
in all three types of GD include hepatosplenomegaly, anemia, bone and joint pain, and lung
disease [Beutler, 1991].
While there is no cure for GD, enzyme replacement therapies (ERTs) were introduced to
the medical community in 1991 as a treatment for non-neurologic symptoms of GD. Therefore,
these courses of treatment have been most effective for treatment in patients with type 1 GD
[Kay et al, 1991; Verderese et al, 1993]. ERT must be given through infusion biweekly over the
course of several hours and many individuals use central venous access devices (CVADs) for
therapy administration. In August, 2014, a new treatment referred to as substrate reduction
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therapy (SRT) was approved by the Food and Drug Administration (FDA) for patients with type
1 GD [Futerman et al, 2004]. This type of therapy is delivered orally once or twice daily
depending on patient metabolizer status and has been proven to be as effective as ERT in
treatment of physical symptoms of the disease throughout its clinical trial [Kamath et al, 2014;
Lukina et al, 2014; Poole, 2014; Mistry et al, 2015].
Although SRT is effective at treating physical manifestations of type 1 GD, little is
known regarding the influence this novel therapy could have on the health related quality of life
(HRQoL) of individuals with this genetic condition. In the past, HRQoL has been used to collect
information about the physical and psychosocial effects of chronic disease on patients’ lives.
Patients with chronic conditions such as fibromyalgia, chronic obstructive pulmonary disease
(COPD), and acquired immunodeficiency syndrome (AIDS) have lower HRQoL than members
of the general population across several different categories including physical and mental
quality of life [Schlenk et al, 1998]. While studies of chronic genetic disorders have historically
focused on identification and treatment of manifestations, learning about HRQoL for patients
with certain genetic conditions may allow health care providers, such as medical geneticists and
genetic counselors, to better understand the disease burden of these individuals and the impact
that their disease has on everyday life [Sprangers & Aaronson, 1992]. Previous studies have
shown that patients with type 1 GD, as well as other LSDs such as Fabry disease and Pompe
disease, have a decreased HRQoL when compared with United States population norms
[Damiano et al, 1998; Hayes et al, 1998; Masek et al, 1999; Gold et al, 2002; Giraldo et al, 2005;
Kanters et al, 2011; Bouwman et al, 2011]. Furthermore, ERT has been shown to improve
HRQoL in patients with type 1 GD [Damiano et al, 1998; Masek et al, 1999; Weinreb et al,
2007].
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Due to the recent availability of SRT for patients with type 1 GD, no study to date has
captured the perception of disease burden and HRQoL in patients that are specifically utilizing
SRT for treatment. Because SRT is an oral therapy, it may impact patients differently, while still
providing the same symptom relief for GD. As a result, HRQoL in patients with type 1 GD using
SRT may be different than what is reported in the literature for patients using ERT. Additionally,
patients who used ERT in the past but who are currently using SRT may report a self-perceived
increase in some aspects of quality of life. In this study, we sought to investigate whether or not
patients using SRT to treat non-neuropathic GD have similar or better HRQoL and perception of
disease burden than those patients using ERT. This information could be instrumental in
educating healthcare providers and patients about the full range of risks and benefits of these
courses of treatments outside of treating the physical manifestations of the disease.

MATERIALS AND METHODS
Participants and Data Collection
A link to a study questionnaire was posted in online group forums consisting of patients
with type 1 GD and their family members, including the Yahoo! Gaucher Disease group
(https://groups.yahoo.com/neo/groups/gaucherdisease/info), the National Gaucher Foundation
(NGF) website (http://www.gaucherdisease.org/), and the National Gaucher Foundation of
Canada (NGF Canada) listserv. Additionally, letters describing the study purpose were sent
electronically to physicians at GD treatment centers, as well as to genetic counselors that belong
to the Metabolic Special Interest Group within the National Society of Genetic Counselors.
These healthcare providers were provided with study access information so that their interested
patients could participate in this research. Electronic advertisements were sent every three weeks
to the online groups and healthcare providers during a collection period ranging from October
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12th, 2015 to January 7th, 2016. To be eligible to participate in this study, individuals had to be
18 years of age or older and have a self-reported diagnosis of type 1 GD. Participants were
informed prior to beginning the survey that two dollars would be donated to the NGF for each
complete survey that was submitted. Participants were also asked to identify if they had
participated in this study previously so that responses would not be duplicated. The total number
of individuals with type 1 GD that this survey reached is unknown due to a paucity of data on the
number of patients approached by the healthcare providers and the degree of overlap between
patient populations and support groups; therefore, a response rate could not be reliably
determined. Research data was collected through REDCap™, a secure electronic survey portal.
Informed consent was obtained as a precursor for individuals to begin the survey. This study
received institutional review board exemption from the University of Texas Health Science
Center (IRB #HSC-MS-15-0388).
Assessment Tools
The study questionnaire was comprised of different sections to assess disease history,
treatment history, HRQoL, and demographics. The questionnaire consisted of mostly forced
choice options with some open-ended questions. None of the items were deemed mandatory in
the questionnaire. The survey was structured with gateway questions so that only applicable
questions would be presented to the participant based on their answers to previous questions. The
portion of the survey measuring HRQoL was executed using the validated tool Short Form-36
Version 2® (SF-36v2®) Health Survey from OPTUM QualityMetric, Inc. [Jenkinson et al, 1999].
The SF-36v2® Health Survey questionnaire consists of 36 items forming eight scales measuring
physical functioning, role physical, bodily pain, general health, vitality, social functioning, role
emotion, and mental health. Scores from each of these eight scales compose total physical
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component scores (PCS) and total mental component scores (MCS) ranging from 0 - 100 using
QualityMetric Health Outcomes™ Scoring Software 4.5. A score of 50 indicates an average
HRQoL score and higher scores on these scales indicate higher HRQoL. Age and gender
matched norm data from the general United States population in 2009 was used for data
comparison [Maruish, 2011]. Individuals currently using SRT that used ERT in the past were
also asked questions about how their satisfaction with different aspects of their life compares
between now and when they were using ERT as their primary treatment for type 1 GD.
Statistical Analyses
Participant responses to the survey were recorded and forced-choice question answers
were entered into STATA®, a statistical software program for data analysis (v. 13. StataCorp LP,
College Station, TX). Frequencies (with percentages) were calculated for all data. SF-36v2® PCS
and MCS for adults using SRT were compared to United States 2009 population norms using a
Wilcoxon signed rank test. PCS and MCS for ERT and SRT treatment groups were compared
and analyzed using a Mann-Whitney test. Kruskal-Wallis, Chi-square, and Spearman correlation
tests were performed to assess potential influence of demographic data including sex, age,
income, education, and marital status on PCS and MCS. Spearman correlation tests were also
used to determine if number of symptoms related to type 1 GD or number of other chronic
conditions apart from type 1 Gaucher disease statistically influenced the PCS or MCS of
participants. Descriptive statistics were used to analyze all other parts of the questionnaire.
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RESULTS
Description of Sample
Forty-seven adults with type 1 GD completed the study questionnaire. Our study
population consisted of 35 (74%) women, 46 (98%) Caucasians, and 29 (62%) individuals of
Ashkenazi Jewish ancestry. Almost all participants (n=41, 87%) lived in the United States at the
time that the survey was administered. Other participants (n=6) reported Canadian or Northern
European residence. Participant current ages ranged from 18 to 78 years old with approximately
one-third of participants falling in each of the following age ranges: 18-40 years, 41-60 years,
and 60-78 years. Most participants who responded to additional demographic questions had
achieved at least an undergraduate degree (n=34, 72%), were married (n=23, 49%), and had an
average total annual household income less than 100,000 dollars per year (n=23, 51%) (Table 1).
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Table 1 - Demographic and Background Characteristics of 47 Participants with Type 1 GD
Characteristic

n

%

Mean Age (Range)
18-40
41-60
61-78
Chose not to answer

49 (18 – 78)
15
18
13
1

33
39
28

Sex
Female
Male

35
12

74
26

Ethnicity
Caucasian
Hispanic/Latino

46
1

98
2

Jewish ancestry
Yes
No

29
18

62
38

Country of residence
United States
Other

41
6

87
13

Highest level of education
Some college or less
College degree or higher

13
34

28
72

Marital status
Married
Single, Divorced, or Widowed

23
24

49
51

Total annual household income
Less than $100,000
$100,000 or greater
Chose not to answer

23
22
2

51
49
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Medical and Treatment History
The median age that participants were diagnosed with type 1 GD was 23 years with an
interquartile range (IQR) of 5 to 39 years of age and responses ranging from 1 to 59 years of age.
Slightly less than two-thirds of participants (n=29, 61%) had one or more chronic conditions in
addition to type 1 GD, the most common being hypertension (n=14), back problems (n=12), and
arthritis (n=12) (Figure 1a). Most participants (n=38) had one or more current symptom of type
1 GD at the time of the survey, the most frequent being fatigue (n=30), enlarged liver (n=15),
and enlarged spleen (n=14) (Figure 1b).
All but one survey participant was receiving some type of therapy as a treatment for type
1 GD at the time of this study (Table 2). The median age that individuals began treatment for
type 1 GD was 38 years of age with an IQR of 21 to 50 years old and responses ranging from
one to 62 years of age. Thirty-two of the 47 participants (68%) reported currently using ERT via
intravenous infusions (Table 2). Twenty-seven of 32 ERT users reported using ERT for more
than five years (84%) and none of these participants had been using ERT for less than one year.
Twenty-four of the 32 ERT users (72%) reported being offered SRT by a physician in the past.
Fourteen of the 47 total participants (30%) reported currently using SRT (Table 2). Fiftyseven percent of these SRT users (n=8) had been using SRT for less than one year, while the
other six had been using SRT for more than one year. Though SRT is only recently clinically
available, one participant started SRT as an investigational therapy prior to this therapy and, as
such, had been using SRT for more than five years. Additionally, all but one SRT user (n=13,
93%) had used ERT in the past. Twelve of these 13 current SRT users (92%) had used ERT for
more than one year before changing treatment methods to SRT.
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Figure 1 - Medical History Information of Survey Participants
(a)

(b)

Figure 1 - (a) Frequency chart for different number of symptoms of type 1 GD that were
reported by survey participants (b) Frequency chart for different number of chronic conditions
reported besides type 1 Gaucher disease by participants
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Table 2 - Current Treatment Method and Length of Therapy Use
Current Treatment Method

n

%

ERT

32

68

0
4
27
1

0
13
84
3

14

30

8
5
1

57
36
7

1

2

Less than 1 year
Between 1 and 5 years
More than 5 years
Did not indicate length of therapy
SRT
Less than 1 year
Between 1 and 5 years
More than 5 years
No current treatment

Reactions Toward SRT
Individuals currently using ERT that had been offered SRT in the past by a physician
(n=24) were asked what reasons contributed to their decision not to use SRT (Table 3). Free
responses to this question were parsed and categorized into four themes including potential or
experienced side effects of SRT (n=13), satisfaction with ERT (n=8), feeling as though there is
not enough research on SRT (n=6), and not having time to do candidate testing for SRT (n=1).
Due to the open-ended nature of the response, at times, more than one theme was applicable to
an individual participant.
Thirteen individuals currently using SRT were asked what reasons contributed to their
decision to use SRT (Table 4). Free responses to this question were categorized into five themes:
convenience of SRT (n=7), less invasive than ERT (n=4), reaction to ERT (n=2), continued SRT
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after FDA study (n=1), and recommended by a doctor (n=1). Similar to the other open-ended
item, more than one theme was occasionally applicable to an individual.
Table 3 - Reasons Cited for Declining SRT
Reason Cited

Frequency

Selected quotes from participants

Side effects of SRT

13

“The possibility of [side effects]…”

Satisfaction with ERT

8

“My physician offered [SRT] as
something to think about, but I chose
not to consider it because ERT works
so well for me.”
“I prefer to have an infusion [every]
14 days than taking tablets every day.”

Not enough research on SRT

6

“I feel like [SRT] is being pushed on
us, which makes me uneasy…. The
drug is too new….”

Have not had SRT candidate
testing

1

“[I] have not had time to do extra
[metabolizer status] tests.”
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Table 4 - Reasons Cited for Using SRT
Reason Cited

Frequency

Selected quotes from participants

Convenience

7

“It is very convenient to take [SRT]
because I can take pills instead of
driving to a facility to take [ERT].”

Less invasive/Hate needles

4

“Less invasive than ERT; less
interference with lifestyle.”

Reaction to ERT

2

“[I] developed a serious allergic
reaction to [ERT] after many years on
it without any problems.”

Continued after FDA studies

2

“I joined an SRT drug study during the
ERT shortage and stayed on SRT after
FDA approval.”

Doctor recommended

1

“My doctor recommended [SRT].”

HRQoL in ERT and SRT Current Users
When compared to median PCS and MCS for normative 2009 SF-36v2® Health Survey
data concerning United States adults which are 53.07 and 52.94, respectively, median PCS and
MCS for current SRT users were slightly lower (p < 0.001 and p = 0.014). The median PCS
resulting from the SF-36v2® Health Survey for the 32 current ERT users was 48.16 (IQR of
41.48 to 53.66), while the median PCS was 49.29 (IQR of 39.37 to 55.53) for the 14 current SRT
users (Figure 2a). No statistically significant difference in PCS was observed between current
ERT and current SRT users (p = 0.756). The median MCS for current ERT and current SRT
users were 50.68 (IQR of 43.76 to 55.76) and 50.08 (IQR of 42.93 to 54.67), respectively (Figure
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2b). Similarly, no significant difference in MCS was discerned between these two treatment
groups (p = 0.650).
When PCS and MCS for all users were stratified by sex, income, education, marital status
and number of other chronic conditions excluding type 1 GD, no statistically significant
influence on PCS and MCS for HRQoL was observed. The number of symptoms related to type
1 GD that a participant experienced was statistically associated with a negative influence on PCS
(p < 0.001) and MCS (p < 0.001). Furthermore, while no association of age and PCS was
observed (p = 0.103), there was a correlation observed concerning increased age and increased
MCS (p = 0.003).
Perceived Changes in HRQoL in SRT Sample
Twelve current SRT users who reported using ERT in the past responded to items
comparing their perceptions of health for both treatments with regard to five health categories:
“general health”, ability to complete everyday activities or “physical ability”, “emotional health”,
“social interactions”, and “satisfaction with life”. More than half (n=7) of the current SRT users
report no difference in their perception of health while using SRT as compared to ERT with
regard to general health, emotional health, social interactions, and satisfaction with life. Twothirds (n=8) of current SRT users report no perception of difference in health between therapy
options with regard to physical ability (Figure 3). Between one and two current SRT users per
health category reported having a somewhat better or much better perception of health while
using SRT as compared to when using ERT. Two participants reported experiencing much worse
health while using SRT than when using ERT for each of these five health categories. These two
participants both indicated in free response items that their only reasons for using SRT were that
they “hate needles” and that they experienced side effects of SRT.
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Figure 2 - Physical and Mental HRQoL Component Scores by Therapy

(a)

(b)

Figure 2 - (a) Boxplot of SF-36v2® Health Survey PCS of current ERT and SRT users by
therapy (b) Boxplot of SF-36v2® Health Survey MCS of current ERT and SRT users by therapy
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Figure 3 - Perceived Changes in HRQoL in SRT Users who Used ERT in Past

Figure 3 - Stacked column chart of SRT users’ perceptions of current health as compared to
health during past use of ERT
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DISCUSSION
GD is the most common inherited LSD, affecting approximately 1 in every 60,000 to
100,000 people worldwide [Meikle et al, 1999; Poorthuis et al, 1999]. Treatment for type 1
Gaucher disease has traditionally been administered in the form of ERT via biweekly
intravenous infusions. However, in August, 2014, an oral SRT was approved by the FDA for
clinical treatment of type 1 GD. While evidence in the literature suggests that the use of ERT
improves HRQoL for individuals with type 1 GD, no study to date has investigated the HRQoL
of those using SRT as a therapy for type 1 GD [Damiano et al, 1998; Masek et al, 1999; Weinreb
et al, 2007].
The most common reasons current ERT users declined the use of SRT were potential or
experienced side effects and satisfaction with ERT. Previous research of therapy preferences in
chronic inherited conditions, such as hemophilia, have shown that risk of side effects are a major
factor in patient preferences for a particular therapy [Scalone et al, 2009; Mohamed et al, 2011;
Chaugule et al, 2015]. This study shows that the risk of side effects as a marker for therapy
preference extends to patients with type 1 GD that considered the switch from ERT to SRT. The
idea that individuals who were satisfied with their use of ERT and, perhaps, were comfortable
with the routine of their bi-weekly intravenous infusions was not a surprising one, especially
considering that greater than 84% of current ERT users had been using ERT for more than five
years. However, it was unexpected that two current ERT users perceived having an intravenous
infusion of ERT every 14 days as more convenient than taking oral tablets as treatment for type 1
GD. These results are possibly a reflection of patients’ preferences for course of treatment. If so,
this may be reminiscent of the resistance to new therapies in the context of other medical
conditions. An investigation of patient preferences for treatment of chronic hematological
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conditions showed that even if new treatments become available, a large percentage of patients
feel uncertain about or refuse change in treatment [Renzi et al, 2015]. Additionally, research
regarding patients with β-thalassemia found that this population may be resistant to switching
from intravenous infusions to oral therapies, perhaps due to conflicted feelings of trying a new
therapy when they are satisfied with a current treatment method [Trachtenberg et al, 2014].
The most common reasons current SRT users cited as contributing to their decision to use
this therapy were convenience and the less invasive nature of SRT. Due to the difference in the
route of administration for ERT and SRT, convenience and less invasiveness were predicted
advantages that current SRT users would cite as reasons for using this new therapy for type 1
GD. Other SRT users mentioned continuing SRT after the FDA clinical trial because this therapy
was effective or that their doctor recommended this type of therapy. These findings mirror
reasons why other patient populations, including those with multiple sclerosis, have switched
therapies in the past. A study of individuals receiving treatment for multiple sclerosis in 2014
revealed that the main reasons cited for switching therapies was because a doctor recommended
the new treatment or because the patient perceived it as an effective treatment option [Salter et
al, 2014].
Median PCS and MCS for individuals using SRT to treat type 1 GD were slightly lower
than median PCS and MCS for United States adults who took the SF-36v2® Health Survey in
2009. Previous studies revealed that individuals with type 1 GD have lower HRQoL than
average and that people with type 1 GD using ERT have increased HRQoL as compared to those
not receiving treatment [Damiano et al, 1998; Masek et al, 1999; Weinreb et al, 2007]. While we
did not specifically compare the HRQoL of current SRT users to those with the type 1 GD that
are not receiving treatment, it is possible that current SRT users may have decreased HRQoL as
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compared to adults without type 1 GD since these individuals still experience a rare and chronic
medical condition that necessitates treatment.
No significant difference in PCS or MCS between current ERT and SRT users was
observed. The use of SRT was hypothesized to increase HRQoL above that of individuals using
ERT to treat type 1 GD since it is considered by many to be a more convenient and less invasive
type of therapy. This hypothesis was not confirmed by this data; however, our findings are
substantial in the investigation of SRT as a newly approved therapy for type 1 GD. This is due to
the demonstration that SRT is, on average, just as effective at maintaining HRQoL in individuals
with type 1 GD as ERT. Moreover, current SRT users that used ERT in the past most often
reported no difference in their perception of different aspects of health when asked to compare
their current health to their health while using ERT. Although self-perceptions of health are
subjective to the individual, it was unexpected that the majority of current SRT users would
perceive no difference in these categories related to HRQoL with respect to the two treatment
options. Of note, two of the 12 respondents for this set of items indicated that each of the five
aspects of their health inquired about were “much worse now with SRT” than when they used
ERT in the past. These two participants also commented that they experienced side effects
related to SRT. While the convenience of SRT may be an attractive component of this treatment
method, if individuals with type 1 GD experience side effects related to their therapy, this may
not be the ideal treatment regimen for these patients.
The study offers considerable strengths relevant to the interpretation of these findings. Of
great importance is that this is the first study to address the potential influence of SRT for type 1
GD on HRQoL, rather than the purely physiological parameters of other research regarding this
novel treatment option. This report is also the first to address participants’ perceptions of why
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individuals have chosen or declined the use of SRT for type 1 GD in comparison to the
traditional intravenous infusion of ERT. Additionally, this study was administered electronically
and, therefore, had participants from across the United States and other countries. This part of
our study design was intentional in order to eliminate the potential sample bias of patients with
type 1 GD at a single treatment center.
Despite these strengths, there are also some limitations with regard to the results of this
study. The number of participants that were current SRT users is small and greater numbers of
current SRT users with type 1 GD would be desired to corroborate these findings in a bigger
sample. While a large sample size is ideal, type 1 GD is a rare disease and, since SRT has only
been clinically available outside of FDA drug trials since August 2014, there are few members of
the GD community currently using SRT. Because SRT is only available to adult patients, there is
the possibility for a larger population to better assess the effects of SRT on HRQoL in the future
as younger patients with type 1 GD become adults and potentially elect SRT. Another potential
bias for this study is that many of the participants were recruited from GD electronic support
forums and the National Gaucher Foundation membership. Selecting study participants from
electronic information and support communities may introduce a sample bias if the responses of
these participants are not comparable to that of the average adult with type 1 GD [Gawlinski et
al, 2009]. Our group corrected for this possible bias by extending invitations to participate to
patients of medical geneticists and metabolic genetic counselors that have type 1 GD. Despite
this, participants were not asked to report how they learned about this study so a reliable
response rate from different participant sources cannot be calculated. Lastly, our sample had a
large proportion of participants that were Caucasian, well educated, and financially successful.
While this may be representative of the type 1 GD population in general as compared to the
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average adult in the United States, this sample makeup could also potentially introduce influence
on the results of this study.
Another important aspect of this study’s analysis is that the SF-36v2® Health Survey was
administered at only one point in time to each participant. Therefore, while current SRT users
were asked to compare various aspects of their self-perceived health as compared to when using
ERT, a more precise comparison regarding the effect of SRT on HRQoL may be obtained in a
study that collects HRQoL scores at various points in time for ERT users with type 1 GD that
switch to SRT. This proposed methodology would allow for matched statistical comparison for
individuals that have used both therapies and also allow for HRQoL comparison depending on
how long participants have used a certain therapy for type 1 GD. Finally, there is no way to
account for all of the factors that may influence someone’s HRQoL. Analysis of sex, income,
education, marital status, and number of chronic conditions other than type 1 GD showed no
statistically significant association with or influence on HRQoL scores for current ERT or
current SRT users. Unsurprisingly, the higher number of symptoms someone experienced as
related to type 1 GD was associated with a lower PCS and MCS. Increase in age also showed a
slight association with increase in MCS within our sample. This is not a typical observation in
the general population but is one that has been seen in individuals with some chronic mental
health disorders [Folsom et al, 2009]. Despite these findings, the small sample size limited the
use of larger multivariable analytic models adjusting for various factors. Furthermore, it is
possible that a factor not accounted for in this survey could influence the PCS and MCS and,
therefore, the HRQoL of all participants.
Overall, the results of this study propose that there is no significant difference in HRQoL
between current ERT and current SRT users for type 1 GD. This is in addition to previous
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literature showing that the efficacy of SRT to treat physical symptoms of type 1 GD is
comparable to traditional ERT [Kamath et al, 2014; Lukina et al, 2014; Poole, 2014; Mistry et al,
2015]. Based on this evidence, the effects of SRT on the individual appear to be similar to those
of ERT unless patients experience side effects related to therapy that could reduce HRQoL.
Furthermore, many patients that use either ERT or SRT cite a variety of reasons, many of which
are individualized, for why they may prefer their current treatment to another option. Together,
these findings suggest that individuals with type 1 GD should be thoroughly counseled about the
risks and benefits of both forms of therapy when beginning treatment or establishing care for this
condition.
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